The NHS in England has started funding Enhertu (trastuzumab deruxtecan) for patients with HER2‑positive metastatic breast cancer, a therapy that clinical trials suggest can add about seven months of overall survival on average.

Enhertu, an antibody‑drug conjugate that delivers a chemotherapy payload directly to cancer cells, received a positive technology appraisal from NICE earlier this year. The appraisal concluded that the drug’s clinical benefit outweighs its cost for patients whose disease has progressed after two or more prior therapies.

"This decision offers new hope for people living with advanced breast cancer," said a spokesperson for NHS England.

In Scotland, the drug has been available on the public formulary for more than two years, where oncology teams have reported improved outcomes and manageable safety profiles. The English rollout follows the same clinical‑grade evidence that underpins the Scottish experience.

Evidence behind the survival gain

Data from the DESTINY‑Breast04 trial, published in 2023, showed that patients receiving Enhertu lived a median of 25.4 months compared with 12.5 months on standard chemotherapy. The trial enrolled over 500 women whose tumours expressed the HER2 protein but had failed prior HER2‑targeted treatments.

Researchers noted that the drug’s design allows it to bind to HER2 on tumour cells, then release a potent cytotoxic agent inside, sparing most healthy tissue. While the therapy can cause side‑effects such as nausea, fatigue and, in rare cases, lung inflammation, clinicians say the benefits outweigh these risks for heavily pre‑treated patients.

How the NHS will deliver the drug

Under the new guidance, specialist oncology centres across England will be able to prescribe Enhertu through the Cancer Drugs Fund, with funding allocated to cover the full course of treatment. Patients must meet strict eligibility criteria – typically having received at least two previous lines of systemic therapy and showing progression on those regimens.

The rollout is being coordinated by NHS England’s Clinical Commissioning Group, which will monitor uptake and outcomes through the national cancer registry. Early‑stage data will be reviewed after the first 12 months to confirm the drug’s real‑world effectiveness and budget impact.

What the approval means for patients and the system

For the estimated 4,500 women in England diagnosed each year with HER2‑positive metastatic disease, the new option expands the therapeutic arsenal beyond traditional chemotherapy and existing HER2‑targeted agents such as trastuzumab and pertuzumab.

Patient advocacy groups have welcomed the move, describing it as a "significant step forward" in a landscape where treatment options have been limited once disease progresses beyond first‑line therapy. They stress that timely access is crucial, as the extra survival months can translate into meaningful quality‑of‑life improvements.

Health‑economics analysts note that while the drug’s price is higher than conventional chemotherapy, the extension of life and potential reduction in hospital admissions for disease complications may offset some of the cost. The NHS will continue to assess cost‑effectiveness as more real‑world data become available.

Clinicians also anticipate that the English experience will feed back into ongoing research, including trials that combine Enhertu with other novel agents. Such combinations could further improve outcomes for patients whose cancers become resistant to single‑agent therapy.

The decision arrives at a time when cancer drug funding is under intense scrutiny across the UK. By aligning with Scotland’s earlier adoption, England signals a willingness to embrace targeted therapies that demonstrate clear survival benefits, even when they carry a substantial price tag.